TOP STORIES

• COMMENTARY Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll
  March 16, 2022

• BUSINESS Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme
  March 16, 2022

• ORGANIZATION API Import Costs from Europe Surging amid Russian Airspace Closures
  March 15, 2022

• ORGANIZATION List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
  March 14, 2022

• BUSINESS Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief
  March 14, 2022

• BUSINESS Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
  March 14, 2022

• BUSINESS Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally
  March 11, 2022

• BUSINESS Chugai Won’t Challenge Edirol Substance Patent Ruling
  March 11, 2022

• REGULATORY Panel Confirms Backing for Alexion’s Bleeding Antidote after Data Integrity Issues
  March 10, 2022

• BUSINESS Japan Drug Makers Moving to Support War-Hit Ukraine
  March 10, 2022

• BUSINESS Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll
  March 9, 2022

• REGULATORY MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
  March 9, 2022

• ORGANIZATION Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official
  March 8, 2022

• BUSINESS SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury
  March 8, 2022

• BUSINESS Eisai Suffers 9%-Plus Cut, Sumitomo Dainippon Over 8% in 2022 Drug Price Revision: Jiho Poll
  March 7, 2022

• REGULATORY Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
  March 4, 2022

• REGULATORY Outgoing Chair of Unapproved Drug Council Boasts 300 Approvals Achieved to Cut Lag, Urges New Reimbursement Scheme
  March 4, 2022

• BUSINESS AZ Japan Working towards 100% Electric Vehicle Fleet by 2025, but Challenges Remain
  March 3, 2022

• REGULATORY Alexion’s Bleeding Antidote Up for PAFSC Discussion Again after Data Integrity Issues
  March 3, 2022

• BUSINESS Zogenix Sees Its Pipeline Drugs Continue to Be Developed in Japan after UCB Deal
  March 2, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 82
• 83
• 84
• 85
• 86
• 87
• 88
• 89
• 90
• …
• Next ›
• 最終 »